Skopos Bio Raises A$12M for Cancer Therapies

Australian biotech Skopos Bio has raised A$12 million to develop targeted radioactive medicines for cancers that are difficult to treat with conventional approaches.

What happened

Melbourne-based Skopos Bio announced an A$12 million seed round with backing from investors including Tenmile, Tin Alley Ventures and Yosemite, a cancer-focused investor founded by Reed Jobs. The company is a spinout of the Peter MacCallum Cancer Centre and was established by researchers Michael Hofman, Mohammad Haskali and Luc Furic. It is developing radiopharmaceutical treatments initially focused on prostate cancer. These therapies pair a cancer-targeting molecule with a radioactive component intended to deliver radiation directly to diseased tissue. The funding will support research and preparation for clinical development. The original announcement was reported around 30 September to 1 October; this is a catch-up item, not a 12 October financing.

Why it matters

Radiopharmaceuticals offer a different approach from radiation delivered by an external machine. If a targeting molecule binds selectively to a cancer-associated marker, it can carry a radioactive payload to disease sites throughout the body. The clinical appeal is potentially more targeted treatment, although unwanted exposure, manufacturing and distribution remain challenges.

The bigger picture

Targeted radiotherapies are attracting interest as drugmakers seek more precise oncology treatments. Skopos draws on an established Australian nuclear-medicine research base, but remains early in development. Its candidates still need rigorous studies of safety, dose selection and efficacy; the financing and specialist investor backing do not substitute for results in patients.